Zentalis Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ZNTL$1.74+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts and par value)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $41,320 | $28,038 |
| Marketable securities, available-for-sale | 349,932 | 454,881 |
| Prepaid expenses and other current assets | 9,018 | 13,799 |
| Total current assets | 400,270 | 496,718 |
| Property and equipment, net | 5,016 | 5,819 |
| Operating lease right-of-use assets | 33,403 | 35,916 |
| Prepaid expenses and other assets | 5,609 | 6,818 |
| Goodwill | 3,736 | 3,736 |
| Restricted cash | 2,627 | 2,681 |
| Total assets | $450,661 | $551,688 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $8,202 | $14,926 |
| Accrued expenses | 46,675 | 54,441 |
| Total current liabilities | 54,877 | 69,367 |
| Long-term lease liability | 40,457 | 43,150 |
| Other long-term liabilities | 996 | 1,780 |
| Total liabilities | 96,330 | 114,297 |
| Commitments and contingencies | ||
| EQUITY | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 71,149,666 and 70,765,554 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 71 | 70 |
| Additional paid-in capital | 1,359,589 | 1,323,576 |
| Accumulated other comprehensive income | 1,594 | 2,194 |
| Accumulated deficit | (1,006,923) | (888,556) |
| Total stockholders’ equity | 354,331 | 437,284 |
| Noncontrolling interests | — | 107 |
| Total equity | 354,331 | 437,391 |
| Total liabilities and stockholders’ equity | $450,661 | $551,688 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.